{
    "Trade/Device Name(s)": [
        "BD Phoenix\u2122M Automated Microbiology System - Nitrofurantoin (8-512 \u03bcg/mL), Trimethoprim-sulfamethoxazole (0.5/9.5-16/304 \u03bcg/mL) and Nalidixic Acid (2-32 \u03bcg/mL)"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K060447",
    "Predicate Device Reference 510(k) Number(s)": [
        "N50510",
        "K020321",
        "K031530",
        "K033907",
        "K030579"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "April 19, 2006",
    "Summary Letter Received Date": "April 20, 2006",
    "Submission Date": "April 19, 2006",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Nitrofurantoin",
        "Trimethoprim-sulfamethoxazole",
        "Nalidixic Acid"
    ],
    "Specimen Type(s)": [
        "Pure culture isolates of Gram-negative and Gram-positive bacteria"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix\u2122M Automated Microbiology System",
        "BD Phoenix instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Broth microdilution",
        "Automated identification and antimicrobial susceptibility testing",
        "Redox indicator for growth detection"
    ],
    "Methodologies": [
        "Broth-based microdilution",
        "Automated bacterial identification",
        "Automated antimicrobial susceptibility testing"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "System",
        "Panel",
        "Reagent",
        "Software",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix\u2122M Automated Microbiology System for rapid identification and antimicrobial susceptibility testing using Nitrofurantoin, Trimethoprim-sulfamethoxazole, and Nalidixic Acid",
    "Indications for Use Summary": "Intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) for most Gram-negative aerobic and facultative anaerobic bacteria (Enterobacteriaceae, Non-Enterobacteriaceae) and Gram-positive bacteria (Staphylococcus, Enterococcus, Streptococcus) isolates from pure culture",
    "fda_folder": "Microbiology"
}